Results 101 to 110 of about 129,849 (338)

Neuroprotective Effect of Ghrelin on Substantia Nigra in Parkinson Disease Model Induced -MPTP [PDF]

بیولوژی کاربردی, 2019
Aim and Background: Parkinson's disease is a progressive central nervous system disorder. This disease is caused by degenerative loss of dopaminergic neurons of midbrain, from substantia nigra to corpus striatum pathway.
Neda Nikoklam Nazif
doaj  

Spiked human substantia nigra proteome data set for use as a spectral library for protein modelling and protein mapping

Data in Brief, 2019
This article describes a mass spectrometric data set generated from human substantia nigra tissue that was spiked with iRT peptides. The data set can be used as a spectral library for analysis of the human brain; especially for analysis of human ...
Simone Steinbach, Bettina Serschnitzki, Manfred Gerlach, Katrin Marcus, Caroline May   +4 more
doaj   +1 more source

Differential Effects of Levodopa and Stimulation on Post‐Surgery Freezing of Gait in Subthalamic Nucleus Deep Brain Stimulation Parkinson's Disease Patients: A Clinical and Kinematic Analysis

Movement Disorders Clinical Practice, EarlyView.
Abstract Background The long‐term efficacy of high‐frequency subthalamic nucleus deep brain stimulation (STN‐DBS) on freezing of gait (FOG) remains unclear. We aimed to study the mechanism and optimal therapeutic approach to long‐term post‐surgery FOG.
Raquel Barbosa, Paulo Bastos, Patrícia Pita Lobo, Catarina Correia Rodrigues, Anabela Valadas, Leonor Correia Guedes, Beatriz Mano, Sara Alberto, Vitor Paixão, Mário Miguel Rosa, Ricardo Matias, Daniel Martins, Marcelo Mendonça, Miguel Coelho   +13 more
wiley   +1 more source

Restricted effects of androgens on glucocorticoid signaling in the mouse prefrontal cortex and midbrain

Frontiers in Endocrinology
Glucocorticoids are key executors of the physiological response to stress. Previous studies in mice showed that the androgen receptor (AR) influenced the transcriptional outcome of glucocorticoid treatment in white and brown adipocytes and in the liver ...
Jorge Miguel Amaya, Jorge Miguel Amaya, Hetty C. M. Sips, Hetty C. M. Sips, Eva M. G. Viho, Eva M. G. Viho, Jan Kroon, Jan Kroon, Onno C. Meijer, Onno C. Meijer   +9 more
doaj   +1 more source

Quantitative Susceptibility Mapping in Parkinson's Disease.

PLoS ONE, 2016
BackgroundQuantitative susceptibility mapping (QSM) and R2* relaxation rate mapping have demonstrated increased iron deposition in the substantia nigra of patients with idiopathic Parkinson's disease (PD).
Christian Langkammer, Lukas Pirpamer, Stephan Seiler, Andreas Deistung, Ferdinand Schweser, Sebastian Franthal, Nina Homayoon, Petra Katschnig-Winter, Mariella Koegl-Wallner, Tamara Pendl, Eva Maria Stoegerer, Karoline Wenzel, Franz Fazekas, Stefan Ropele, Jürgen Rainer Reichenbach, Reinhold Schmidt, Petra Schwingenschuh   +16 more
doaj   +1 more source

Disease modifying therapy for multiple system atrophy – Parkinsonian Type [PDF]

, 2017
BACKGROUND: Multiple System Atrophy –Parkinsonian Type (MSA-P) is a rare, rapidly progressive neurodegenerative disease without any current treatment.
Dwyer, Sean Sullivan
core  

A Real‐World Study on Unstable Parkinson's Disease: Levodopa Dosage Management and the Role of Nonmotor Symptoms

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a neurodegenerative disorder associated with motor and nonmotor symptoms. Objectives This study assesses levodopa dose management, the therapeutic goals of clinicians, the factors that influence clinicians' choice of therapy, and the role of nonmotor symptoms using real‐world evidence from Germany, Italy,
Fabrizio Stocchi, Jaime Kulisevsky, Wolfgang H. Jost   +2 more
wiley   +1 more source

Reduction of alpha-synuclein oligomers in preclinical models of Parkinson’s disease by electrical stimulation in vitro and deep brain stimulation in vivo

Brain Stimulation
Background: Deep brain stimulation (DBS) has been widely used to manage debilitating neurological symptoms in movement disorders such as Parkinson's disease (PD).
Eun Jung Lee, David Hernán Aguirre-Padilla, Anton Fomenko, Grishma Pawar, Minesh Kapadia, Jimmy George, Andres M. Lozano, Clement Hamani, Lorraine V. Kalia, Suneil K. Kalia   +9 more
doaj   +1 more source

Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, managing symptoms becomes increasingly difficult. Foslevodopa/foscarbidopa (LDp/CDp), a 24‐hour/day continuous subcutaneous infusion of levodopa/carbidopa (LD/CD) prodrugs, improves motor complications.
Jason Aldred, Manon Bouchard, Juan Carlos Martínez‐Castrillo, Michael J. Soileau, Amy M. Spiegel, Lars Bergmann, Resmi Gupta, Megha B. Shah, Pavnit Kukreja, David G. Standaert, Stuart H. Isaacson, Tove Henriksen   +11 more
wiley   +1 more source

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson\u27s Disease. [PDF]

, 2019
While GM1 may interact with α-synuclein in vitro to inhibit aggregation, the ability of GM1 to protect against α-synuclein toxicity in vivo has not been investigated.
Aras, Radha, Brotchie, Jonathan M., Koprich, James B., Schneider, Jay S., Singh, Vikrant, Williams, Courtney K.   +5 more
core   +1 more source